Skip to main content

Table 1 Relationship between NDRG2 promoter methylation, patient clinical characteristics, PA invasiveness and NDRG2 mRNA expression

From: N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma

 

NDRG2 gene methylation

 

Number of patients

M (%)

U (%)

p-value

Cases

119

27 (22.69)

92 (77.31)

 

Age (years)

 ≤60

48

13 (27.08)

35 (72.92)

0.368

 >60

70

14 (20.00)

56 (80.00)

Gender

 Female

68

15 (22.06)

53 (77.94)

0.850

 Male

51

12 (23.53)

39 (76.47)

PA function

 Secreting

61

15 (24.59)

46 (75.41)

0.612

 Non-secreting

58

12 (20.69)

46 (79.31)

Relapse

 Appear

10

2 (20.00)

8 (80.00)

0.832

 None

109

25 (22.94)

84 (77.06)

Prolactinoma

 Appear

37

9 (24.32)

28 (75.68)

0.952

 None

24

6 (25.00)

18 (75.00)

Acromegaly

 Appear

12

4 (33.33)

8 (66.67)

0.433

 None

49

11 (22.45)

38 (77.55)

Cushing syndrome

 Appear

1

0 (0.00)

1 (100.00)

0.565

 None

60

15 (25.00)

45 (75.00)

Hormones

 PRL

37

9 (24.32)

28 (75.68)

0.801

 IGF-1

2

0 (0.00)

2 (100.00)

0.401

 GH

6

2 (33.33)

4 (66.67)

0.639

 ACTH

1

0 (0.00)

1 (100.00)

0.556

 Multiple

13

4 (30.77)

9 (69.23)

0.616

Invasiveness

 Invasive

41

10 (24.39)

31 (75.61)

0.452

 Non-invasive

19

3 (15.79)

16 (84.21)

NDRG2 mRNA expression

 Low

22

3 (13.64)

19 (86.36)

 

 Medium

50

13 (26.00)

37 (74.00)

0.458

 High

37

7 (18.92)

30 (81.08)

  1. M methylated, U unmethylated, PRL prolactin, IGF-1 insulin-like grow factor 1, GH growth hormone, ACTH adrenocorticotropic hormone, multiple PAs secreting more than one hormone